Literature DB >> 11707056

Risk of torsades de pointes from oral erythromycin with concomitant carbimazole (methimazole) administration.

T W Koh1.   

Abstract

There are many reports of intravenous erythromycin causing QT prolongation and torsades de pointes, but this complication is seldom ascribed to orally administered erythromycin, which is by far the most commonly prescribed route. This report describes a case of torsades de pointes associated with oral erythromycin as a result of a previously undescribed interaction with carbimazole, an antithyroid drug that is metabolized to the active drug methimazole, and the potential pharmacokinetic and pharmacodynamic mechanisms are highlighted.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11707056     DOI: 10.1046/j.1460-9592.2001.01575.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  12 in total

Review 1.  Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death.

Authors:  Deborah L Wolbrette
Journal:  Curr Cardiol Rep       Date:  2004-09       Impact factor: 2.931

2.  Azithromycin and the risk of cardiovascular death.

Authors:  Wayne A Ray; Katherine T Murray; Kathi Hall; Patrick G Arbogast; C Michael Stein
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

3.  Use of azithromycin and risk of ventricular arrhythmia.

Authors:  Gianluca Trifirò; Maria de Ridder; Janet Sultana; Alessandro Oteri; Peter Rijnbeek; Serena Pecchioli; Giampiero Mazzaglia; Irene Bezemer; Edeltraut Garbe; Tania Schink; Elisabetta Poluzzi; Trine Frøslev; Mariam Molokhia; Igor Diemberger; Miriam C J M Sturkenboom
Journal:  CMAJ       Date:  2017-04-18       Impact factor: 8.262

4.  Advantages of azithromycin over erythromycin in improving the gastric emptying half-time in adult patients with gastroparesis.

Authors:  Jean M Larson; Anna Tavakkoli; Walter E Drane; Phillip P Toskes; Baharak Moshiree
Journal:  J Neurogastroenterol Motil       Date:  2010-10-30       Impact factor: 4.924

5.  A suspected case of carbimazole-associated torsades de pointes.

Authors:  Chiranjib Bagchi; Dhurjati Prasad Sinha; Santanu Kumar Tripathi
Journal:  Indian J Pharmacol       Date:  2010-02       Impact factor: 1.200

6.  Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study.

Authors:  Henrik Svanström; Björn Pasternak; Anders Hviid
Journal:  BMJ       Date:  2014-08-19

7.  Estimated Cardiac Risk Associated With Macrolides and Fluoroquinolones Decreases Substantially When Adjusting for Patient Characteristics and Comorbidities.

Authors:  Linnea A Polgreen; Benjamin N Riedle; Joseph E Cavanaugh; Saket Girotra; Barry London; Mary C Schroeder; Philip M Polgreen
Journal:  J Am Heart Assoc       Date:  2018-04-21       Impact factor: 5.501

8.  Erythromycin, QTc interval prolongation, and torsade de pointes: Case reports, major risk factors and illness severity.

Authors:  Jules C Hancox; Mehrul Hasnain; W Victor R Vieweg; Michael Gysel; Michelle Methot; Adrian Baranchuk
Journal:  Ther Adv Infect Dis       Date:  2014-04

9.  Prevalence of potential drug interactions in an Iranian general hospital.

Authors:  G Sepehri; P Khazaelli; F Arabpour Dahooie; E Sepehri; M R Dehghani
Journal:  Indian J Pharm Sci       Date:  2012-01       Impact factor: 0.975

Review 10.  Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.

Authors:  Janet Sultana; Paola Maria Cutroneo; Salvatore Crisafulli; Gabriele Puglisi; Gaetano Caramori; Gianluca Trifirò
Journal:  Drug Saf       Date:  2020-08       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.